Navigation Links
Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
Date:5/29/2013

Geneva, Switzerland (PRWEB) May 29, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today it will host a free webinar to educate scientists and researchers about the newly launched SURE CHO-Mplus™ Library to address a broad range of protein production bottlenecks, including metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications to boost the overall expression of therapeutic protein drugs.

Entitled “The Selexis SURE CHO-Mplus™ Library - A Novel and Powerful Advancement in Biologic Protein Expression,” the 60 minute webinar will begin at 4:00 PM CEST | 10:00 AM EDT | 7:00 AM PDT on Wednesday, June 19, 2013.

Registration URL: https://attendee.gotowebinar.com/register/1073373288445877504
Webinar ID: 123-386-987

In this webinar you will learn:

  •     An overview of the SURE CHO-M production cell line
  •     The construction of the SURE CHO-Mplus™ combinatorial library
  •     How to implement the SURE CHO-Mplus™ Library platform to efficiently advance drug discovery and protein production programs
  •     Case studies utilizing the SURE CHO-Mplus™ Library

Who should attend?

  •     Any scientist working with recombinant protein either as a target or as a future drug
  •     Cell line development scientists and researchers
  •     Biologics development scientists
  •     Cellular biochemists

When:
Wednesday, June 19, 2013
4:00 PM CEST | 10:00 AM EDT | 7:00 AM PDT
50 minute presentation
10 minute Q/A

Webinar Abstract:
The Selexis SURE CHO-Mplus™ Library - A Novel and Powerful Advancement in Biologic Protein Expression

With certain recombinant proteins, optimal expression cannot be achieved by elevated transcription alone. Low productivity can be the result of a myriad of issues including faulty cleavage and protein precipitation, improper folding, metabolic overload, or backlog in protein translocation or vesicle trafficking. Within Selexis’ SURE CHO-Mplus™ Library a variety of cellular pathway components have been modified to address specific bottlenecks, such as aberrant glycosylation, improper protein folding, metabolic or translation issues. The SURE CHO-Mplus™ Library has been shown to significantly improve production levels of a broad range of proteins including difficult-to-express monoclonal antibodies, enzymes, structural proteins and fusion proteins such as Fc-fusions and minibodies.

About the Speaker:
Pierre-Alain Girod, PhD, Chief Scientific Officer
Dr. Girod joined Selexis in 2006 and was promoted to Chief Scientific Officer in 2007. Dr. Girod studied and received his PhD from the University of Lausanne. Prior to joining Selexis, Dr. Girod worked at the Department of Biology at the University of Lausanne in the field of targeted protein degradation. Earlier in his career, Dr. Girod completed a postdoctoral fellowship at the University of Wisconsin-Madison in the degradation of proteins by the ubiquitin pathway. In 1993 he returned to Switzerland where he discovered a family of genetic sequences involved in the epigenetic regulation of genes. This discovery has subsequently been used to by pharmaceutical and biotechnology companies to boost expression of therapeutic proteins.
Where:
Registration URL: https://attendee.gotowebinar.com/register/1073373288445877504
Webinar ID: 123-386-987

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:

Read the full story at http://www.prweb.com/releases/webinar_therapeutic_drug/cell_line_development/prweb10777507.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Institute for Healthcare Advancement will Honor Four for Excellence in Health Literacy at National Conference
2. Advancement In Door Security Combines Delayed Egress And Latch Retraction In One Panic Hardware Device
3. PharmaSmart® and Kinney Drugs Partner up to Unveil Newest Advancement in Pharmacy-Based Biometric Screening and Mobile Interoperability
4. Joslins Susan Bonner-Weir, Ph.D., named American Association for the Advancement of Science Fellow
5. LaStone Launches Merger with TIR Massage Stone To Further The Advancement of Massage Therapy Education in 2012
6. Silk and cellulose biologically effective for use in stem cell cartilage repair
7. Frequently used biologic agents might cause acute liver injury
8. Men Biologically Programmed to Steer Clear of Friends Wives
9. Dog Study Raises Prospect of Biological Pacemaker for Humans
10. Medicines quality workshop to address standards for microbiological contamination, bioburden control
11. Dr. Daniel Strader of Dallas Designer Smiles Receives Top Reviews as Local Dallas, TX Dentist for Biological Dentistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... responds to and which He does not. Yisrayl says with so many titles and ... true name, but he says with a little Scripture, backed with a lot of research, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced the ... implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software ... in long-term care, Brooke Grove now has the capability to achieve its goal ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Rob Lowe is ... now he has leant his presence to an educational purpose as the host of ... important one being cancer. In a recent episode, the series focuses on thyroid cancer. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
Breaking Medicine Technology: